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Abstract
Objectives—The Systemic Capillary Leak Syndrome (SCLS) is a rare and potentially fatal 
disorder resembling systemic anaphylaxis that is characterized by transient episodes of 
hypotensive shock and peripheral edema. The pathogenesis of SCLS is unknown, and triggers for 
attacks are apparent only in a minority of patients. We introduce a clinical algorithm for the 
diagnosis of SCLS, and we investigated potential serum biomarkers of acute SCLS episodes.
Methods—We analyzed serum cytokines in a cohort of 35 patients with an established diagnosis 
of SCLS and characterized the effects of SCLS sera on endothelial cell function. We investigated 
the cellular source(s) of CXCL10, a chemokine that was significantly elevated in both basal and 
acute SCLS sera, by flow cytometry.
Results—Several cytokines were elevated in acute SCLS sera compared to baseline or sera from 
healthy controls, including CXCL10, CCL2, IL-1β, IL-6, IL-8, IL-12 and TNFα. The majority of 
acute sera failed to activate endothelial cells as assessed by surface adhesion marker expression. 
Monocytes appear to be the major source of serum CXCL10, and the percentage of CXLC10+ 
monocytes in response to IFNγ stimulation was increased in SCLS subjects compared to controls.
Conclusions—The presence of proinflammatory cytokines in acute SCLS sera suggests that 
inflammation or infection may have a role in triggering episodes. The enhanced capacity of 
monocytes from SCLS patients to produce CXCL10 suggests a new therapeutic avenue for SCLS.
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tIntroduction
The Systemic Capillary Leak Syndrome (SCLS) is a life-threatening disorder that occurs 
sporadically, typically in middle-aged Caucasians [1,2]. SCLS is characterized by recurrent, 
reversible episodes of distributive shock and anasarca due to sudden and unexplained 
leakage of plasma into the tissues. SCLS resembles, and is often erroneously diagnosed as, 
more common disorders such as sepsis, angioedema, and systemic anaphylaxis. Although a 
monoclonal gammopathy of unknown significance (MGUS) is highly associated with SCLS 
[3,4], its pathophysiologic significance is unclear. Therefore, because no specific biomarkers 
or pathognomonic clinical sign(s) of SCLS exist currently, the triad of transient hypotension, 
hemoconcentration, and serum hypoalbuminemia in the absence of underlying causes is 
sufficient to establish the diagnosis [2,5,6]. Fewer than 250 cases have been reported since 
Clarkson described SCLS in 1960 [2]. There is no specific treatment for acute SCLS other 
than hemodynamic support with intravenous fluids and vasopressors. Drugs such as 
theophylline, β2-adrenergic agonists, and most recently, imatinib, have been used as 
prophylactic agents to promote vascular integrity in SCLS [6]. Based on anecdotal evidence 
accumulated over several years, it has become apparent that monthly intravenous 
immunoglobulin (IVIG, 2 g/kg) infusions have severely curtailed attacks in a majority of 
patients who receive this therapy indefinitely [6–8].
Most research findings on SCLS have been based on single case reports, or purely clinical 
observations [2,6]. Using samples from our (then) 23-patient cohort, we reported previously 
that sera from SCLS patients during acute disease intervals uniformly induced 
hyperpermeability of human microvascular endothelial cell (HMVEC) monolayers due to 
disruption of endothelial adherens junctions and actin stress fiber formation [4]. In contrast, 
sera from these patients obtained during remission had little to no impact on HMVEC 
barrier integrity and resembled sera from healthy controls. HMVEC hyperpermeability 
elicited by acute SCLS sera was inhibited by pretreatment of target endothelial cells with 
IVIG or by antibody neutralization of Angiopoietin-2 (Ang2), a known mediator of vascular 
permeability that was elevated in acute SCLS sera compared to sera from healthy donors [4].
Although the trigger(s) of acute SCLS episodes are unclear, a longitudinal case registry 
study of 28 SCLS patients found that about three quarters of subjects experienced flu-like 
symptoms prior to attack onset [6]. Analysis of our expanded cohort (35 subjects) revealed 
elevated levels of several proinflammatory cytokines in acute sera, particularly CXCL10. 
Monocytes from a subset of these patients demonstrated an increased capacity for CXCL10 
production. These results suggest a potential role for CXCL10 in the initiation of acute 
SCLS.
Materials and Methods
Study subjects
Patients were diagnosed with SCLS and classified according to established criteria described 
previously [2,6]. Patients were seen at the Clinical Center of the National Institutes of 
Health. Written informed consent was obtained from each patient, and the study protocol 
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t(09-I-0184) conformed to the ethical guidelines of the 2008 Declaration of Helsinki as 
reflected in a priori approval from the Institutional Review Board of the National Institute of 
Allergy and Infectious Diseases of NIH. Age-, sex-, and race-matched serum samples and 
lymphapheresis samples were obtained from the NIH Blood Bank.
Cells and reagents
Human umbilical vascular endothelial cells (HUVECs) were purchased from American 
Tissue Type Collection. Endothelial Growth Medium (EGM) 2 was obtained from Lonza. 
AlexaFluor 647-conjugated anti-ICAM1, phycoerythryin-conjugated anti-VCAM1, anti-
CXCL10, phycoerythryin/Cy7-conjugated anti-CD14 antibodies and the protein transport 
inhibitor monensin were purchased from BioLegend. Phycoerythryin-Cy5-conjugated anti-
E-selectin and APC-conjugated anti-CD19 antibodies were obtained from BD Biosciences. 
Qdot 605-conjugated anti-CD3 and Live/Dead fixable violet dead stain kit were from Life 
Technologies. Recombinant human TNFα and IFNγ, and CXCL10 Quantikine ELISA kit 
were purchased from R & D Systems.
Cytokine measurements
Serum cytokines were measured using a Bio-plex Pro human cytokine 27-plex and a 
customized human cytokine 9-plex assay kit purchased from Bio-Rad according to the 
manufacturer’s instructions.
Endothelial activation marker analysis
HUVECs were seeded in 6-well plate and incubated overnight at 37°C. Cells were incubated 
with test serum (10% vol/vol final concentration) in growth medium for 4 hours. The cells 
were then detached with CellStripper (Mediatech), washed once with PBS, and stained with 
the indicated antibodies for 30 minutes. Cells were then washed twice, fixed with 4% 
paraformaldehyde for 10 minutes, and analyzed by flow cytometry.
CXCL10 measurement by ELISA
HUVECs were seeded in 96-well plate overnight at 37°C, and followed by incubation with 
test sera (10% vol/vol final concentration) in growth medium for 24 hours. Cell culture 
supernatants were collected and analyzed for CXCL10 by ELISA.
PBMC isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from lymphapheresis samples 
using lymphocyte separation medium (LSM, LP BioMedicals). Briefly, apheresis samples 
were diluted 1:1 in PBS, and 30 ml of diluted sample was overlaid on onto LSM (15 ml) in a 
50 ml conical tube. Samples were centrifuged at 800 × g in a tabletop centrifuge at room 
temperature for 40 minutes with break off.
Flow cytometric analysis of CXCL10 production
PBMCs were left untreated or stimulated with IFNγ (20 ng/ml) in the presence of monensin 
overnight in 37°C. The following day cells were stained with Live/Dead violet staining kit 
according to manufacturer’s instructions and fixed in 4% paraformaldehyde. Fixed cells 
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twere permeabilized with blocking buffer (0.1% saponin, 1 mM CaCl2, 1 mM MgSO4, 0.1% 
BSA, 10 mM HEPES, 5% milk, and 5% human Fc receptor inhibitor, in PBS) for 30 
minutes followed by staining with antibodies in blocking buffer for additional 30 min. 
Stained cells were washed twice and analyzed using LSRII flow cytometer (BD 
BioSciences).
Statistical analysis
Data were analyzed with the GraphPad Prism 6 software package. 1-way ANOVA or 
Kruskal-Wallis (for multiple groups) was used for grouped cytokine analyses, and unpaired 
parametric Student’s t test was used for flow analysis of CXCL10 production. P values < 
0.05 were considered significant.
Results
Algorithm for the diagnosis of SCLS
SCLS should be considered in a patient with unexplained, transient hypotension and/or 
peripheral edema (Figure 1). If a temporally linked exposure (e.g. food, insect venom, drug) 
is suspected, elevated serum tryptase should exclude systemic anaphylaxis. Although our 
experience and that of others [6,9] suggest that acute triggers for SCLS attacks are often 
absent, viral-type upper respiratory and/or systemic symptoms may be present in many 
patients with SCLS prior to the onset of an episode. While catastrophic SCLS attacks are 
typically accompanied by massive edema of the face, trunk, and peripheral extremities, 
swelling resembling angioedema may be confined to certain areas (periorbital, back, and 
abdomen) in less severe episodes. Thus, complement factor 1 esterase inhibitor (C1 INH) 
levels and function should be evaluated in all patients with suspected SCLS to rule out 
hereditary or acquired angioedema.
A hallmark of severe acute SCLS episodes is hemoconcentration due to the loss of water and 
solutes into the extravascular space. Marked elevations in serum hemoglobin over the 
patient’s baseline, often greater than 20 g/dL, are common, occasionally leading to an 
erroneous diagnosis of polycythemia vera [10]. In contrast to cases of dehydration and 
sepsis, the hemoconcentration and hypotension of SCLS do not reverse immediately 
following administration of intravenous fluids and/or vasopressors. Central venous pressures 
remain low (typically <2 mm Hg) in the acute SCLS leak phase, and massive intravenous 
saline infusion often aggravates peripheral edema and can elicit compartment syndromes in 
the extremities.
Serum hypoproteinemia due to protein extravasation is universally present in acute SCLS, 
and albumin levels of <2 g/dL are common. Some patients may present with persistent, 
noncyclical, peripheral edema and hypoalbuminemia, and this subset may or may not 
experience acute hypotensive episodes. These patients are classified as having “chronic” 
SCLS and may also present with visceral (pleural, pericardial) effusions. Finally, it should 
be emphasized that although MGUS is present in 85–95% of SCLS cases, it is not required 
for the diagnosis.
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We evaluated 35 patients with a confirmed diagnosis of SCLS based on the criteria outlined 
above and exclusion of other primary causes of hypotension and/or edema (Table 1). The 
median age at the time of the SCLS diagnosis was 46 years (range 22 months to 66 years) 
although the vast majority of patients experienced clinical symptoms attributable to SCLS 
for several years prior to receiving the actual diagnosis. All but one patient was Caucasian, 
and 43% were female. Our cohort included three children and three adult patients with 
chronic edema. Most subjects experienced at least two episodes of SCLS per year, but the 
range varied widely, from once in five years to weekly. Overall, 86% had MGUS, and 27/29 
M-proteins were of the IgG isotype. M-proteins were not detected in any of the children, 
whereas they were present in 91% of adults with SCLS. While most patients were treated 
with theophylline and terbutaline following diagnosis, 79% (23/29) experienced 
breakthrough episodes while on this regimen. Currently, 63% are treated with monthly 
infusions of IVIG (2 g/kg), and the majority of these patients (20/22) have been essentially 
episode-free for periods of up to eight years. One patient, a seven-year old child, is receiving 
subcutaneous IG because of IVIG intolerance. Two somewhat atypical patients (Pt. 3 and Pt. 
31) experienced recurrent episodes of idiopathic hypotension, hemoconcentration, and 
hypoalbuminemia consistent with the diagnosis of SCLS, yet presented with unique 
symptomatology and did not respond at all to standard SCLS therapy, including IVIG. These 
patients also had M-protein isotypes unusual for SCLS (IgA or IgM, respectively).
Serum cytokine analysis of SCLS
Although nearly one quarter of subjects reported flu-like symptoms prior to the onset of a 
full-blown attack [4], whether this prodrome represents a concomitant infection or is a 
primary feature of SCLS is unknown. Our previous studies that include a cohort of 23 SCLS 
subjects demonstrated that some (VEGF, Ang 2), but not all (IL-2), soluble mediators of 
inflammation were increased in acute SCLS sera [4]. To assess the role of infection and/or 
inflammation in acute SCLS episodes and to discover new mediators that may contribute to 
disease onset and/or severity, we analyzed a panel of 27 serum cytokines in sera from 31 
SCLS patients in remission, 14 SCLS patients with acute symptoms (samples were not 
available from all patients), and 37 healthy controls by multiplex bead assay. Ten cytokines 
(IL-2, IL-4, IL-5, IL-10, IL-13, IL-15, IL-17, G-CSF, GM-CSF, CCL3) were absent or 
present at very low levels in most sera tested, while levels of the cytokine RANTES were 
present at levels above the detectable assay range in all samples. Quantities of eight 
cytokines (IL-1RA, IL-7, IL-9, bFGF, PDGFb, CCL4, and CCL11) did not differ 
significantly among the groups or between individual SCLS subjects. Consistent with our 
previous findings, VEGF was increased in acute SCLS sera compared with sera from 
healthy controls (Figure 2A). We detected significantly increased levels of seven cytokines 
in acute SCLS sera relative to sera from healthy donors, specifically, CXCL10, CCL2, 
IL-12, IL-1β, IL-6, IL-8, and TNFα (Figures 2B–2H). Of all cytokines measured, only 
CXCL10 was significantly increased both in baseline and acute SCLS sera relative to 
controls (Figure 2B). These data suggested that TH1-associated inflammation or infection is 
associated with acute SCLS episodes.
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tActivation of vascular endothelial cells by acute SCLS sera
Skin biopsies of SCLS patients have revealed the presence of perivascular leukocytic 
inflammation during acute episodes in some cases [11]. Proinflammatory cytokines 
including TNFα and IL-8 have been shown to increase adhesion molecule surface 
expression on endothelial cells, which in turn promotes leukocyte rolling, migration and 
extravasation [12]. To determine whether factors in SCLS sera could evoke endothelial 
barrier dysregulation by inducing leukocyte adhesion, we incubated HUVECs with acute 
and baseline sera from SCLS subjects or healthy donors and analyzed surface expression of 
E-selectin, VCAM-1 and ICAM-1 by flow cytometry. Unexpectedly, among the SCLS sera 
tested (20 baseline and 13 acute) only Pt. 3’s episodic serum induced upregulation of these 
adhesion molecules in HUVECs (Figure 3A–B). Surface expression of these markers 
induced by Pt. 3’s episodic sera was comparable to that evoked by TNFα (Figure 3A, dotted 
line) [13], a well-known endothelial activator that served as positive control for these 
experiments. The concentration of TNFα in Pt. 3’ episodic serum (top square dot in Figure 
2G) is comparable to that used in control experiments, 20-fold higher than that found in 
most of other SCLS sera (Figure 2G). These results and the unresponsiveness of HUVECs to 
acute SCLS serum samples containing low levels of TNFα suggest that TNFα is probably 
the cytokine that mediated endothelial adhesion/activation marker upregulation in Pt. 3’s 
episodic sera. Since endothelial cells have the capacity to produce CXCL10 in response to 
inflammatory stimuli [14], we examined whether they produced CXCL10 following 
treatment with SCLS sera. We incubated HUVECs with acute or baseline sera from healthy 
controls or subjects with SCLS for 24 hours and measured CXCL10 in culture supernatants. 
TNFα plus IFNγ served as a positive control, as described in previous work [14,15]. None 
of the SCLS sera tested elicited CXCL10 secretion from HUVECs (Figure 3C). Taking 
together, these results suggested that in classic SCLS, endothelium is probably not the major 
source of CXCL10.
Increased CXCL10-producing monocytes in SCLS subjects
CXCL10, which is induced by many proinflammatory factors such as IFNγ, is secreted by 
many cell types including monocytes, endothelial cells, and fibroblasts during inflammation 
or infections [16]. To determine the cellular source of CXCL10 in SCLS sera, we studied 
whether CXCL10 production by peripheral blood mononuclear cells differed in control 
subjects and those with SCLS. As expected, percentages of PBMCs producing CXCL10 
constitutively were low (data not shown), but INFγ elicited dramatic increases in the number 
of CXCL10+ cells (Figure 4A). Whereas percentages of CXCL10+ T and B lymphocytes 
were low, about 30% of monocytes from healthy control subjects produced CXCL10 
following IFNγ stimulation. Greater than 90% of all CXCL10-producing non-B non-T cells 
were monocytes (CD14+) (Figure 4A, lower right panel). Following IFNγ treatment, we 
detected a significantly higher number of CXCL10+ mononuclear cells and CXCL10+ 
monocytes in SCLS subjects compared to healthy controls (Figures 4B–4C). These results 
suggested that monocytes from subjects with SCLS have increased responsiveness to an 
inflammatory stimulus (IFNγ).
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Among an extensive group of proinflammatory cytokines studied, we found that elevations 
in CCL2, IL-1β, IL-6, IL8, IL-12 and TNFα were associated with acute SCLS episodes, and 
CXCL10 levels were both constitutively and acutely increased in SCLS sera. CXCL10 
appears to be derived principally from peripheral monocytes, and SCLS patients have 
significantly more circulating monocytes with the capacity to make CXCL10 than controls.
We demonstrated increased VEGF levels in acute SCLS sera, which corroborated our 
previous ELISA results in sera from nine SCLS subjects (also included in the current group) 
[4], indicating that VEGF is a potential mediator of endothelial barrier dysfunction in SCLS. 
Although symptoms associated with viral infections do not precede SCLS episodes in all 
cases, some patients report episodes triggered by infections. Accordingly, we found 
increased quantities of CCL2, IL-1β, IL-6, IL-8, IL-12 and CXCL10 in SCLS acute sera, 
suggesting that type 1 immune responses TH1 (e.g. chronic viral, bacterial, or protozoan 
infections), rather than TH2 allergic immunity, may contribute the SCLS phenotype in at 
least a fraction of patients.
Of all cytokines studied, CXCL10 was prominently elevated in both basal and acute SCLS 
sera relative to controls. CXCL10 has been shown to inhibit endothelial cell proliferation 
and induce apoptosis [17], a mechanism previously implicated in the pathogenesis of SCLS 
[18,19]. However, we were unable to demonstrate endothelial apoptosis induced by acute 
SCLS sera in our previous study [4]. In the current work, acute SCLS sera failed to activate 
endothelial cell adhesion marker expression (with one exception), and none of the sera 
elicited CXCL10 production by endothelial cells, suggesting that endothelial cells may not 
be a major source of CXCL10 in SCLS. Although IFNγ is a strong inducer of CXCL10, 
many TH1-associated cytokines are able to increase CXCL10 production by monocytes and 
macrophages. Because IFNγ levels were similar in SCLS and control sera, other factors 
including VEGF, TNFα, IL-β and IFNγ may act synergistically to elicit CXCL10 production 
by monocytes/macrophages in SCLS [20–22]. IFNγ-independent CXCL10 production may 
also occur [23]. For example, a single polynucleotide polymorphism (SNP) in the Cxcl10 
promoter (−135G>A) enhanced its transcriptional activity in tuberculosis [24]. Thus, 
mutations or polymorphisms in Cxcl10 could also account for aberrant CXCL10 production 
in SCLS.
Because elevated serum levels of CXCL10 have been observed in many diseases including 
rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis [25], and HIV 
infection [16], it probably has no utility as a specific diagnostic marker for SCLS. However, 
it may be useful for diagnosis and/or prognosis when considered with previously identified 
permeability mediators VEGF and Ang2. CXCL10 is a potent chemoattractant for 
monocytes/macrophages and activated T cells and promotes leukocyte transmigration 
through endothelium into inflamed tissues. Further study of abnormal CXCL10 production 
and its cellular source(s) may provide insights into the initial permeability-inducing trigger 
in SCLS episodes as well as uncover new therapeutic strategies for this potentially fatal 
disorder.
Xie et al. Page 7
J Clin Cell Immunol. Author manuscript; available in PMC 2014 November 15.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tAcknowledgments
We thank Dr. Helene Rosenberg for helpful discussions and critical review of the manuscript.
Funding
This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious 
Diseases, National Institutes of Health (Project AI001830, K.M.D). Support by M.Y. for this project was funded in 
whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract 
No. HHSN261200800001E. S.M.P. is supported by grants from the National Institutes of Health (R01-HL093234 
and R01-DK095072) and the American Diabetes Association (1-13-BS-1-41).
Abbreviations
SCLS Systemic Capillary Leak Syndrome
HUVEC Human Umbilical Vein Endothelial Cells
PBMC Peripheral Blood Mononuclear Cells
ICAM-1 Intercellular Adhesion Molecule-1
VCAM-1 Vascular Cell Adhesion Molecule-1
IVIG Intravenous Immunoglobulin
IFNγ Interferon Gamma
TNFα Tumor Necrosis Factor α
VEGF Vascular Endothelial Growth Factors
Ang2 Angiopoietin 2
MGUS Monoclonal Gammopathy of Unknown Significance
References
1. CLARKSON B, THOMPSON D, HORWITH M, LUCKEY EH. Cyclical edema and shock due to 
increased capillary permeability. Am J Med. 1960; 29:193–216. [PubMed: 13693909] 
2. Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 
2010; 153:90–98. [PubMed: 20643990] 
3. Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, et al. Idiopathic systemic capillary 
leak syndrome (Clarkson’s disease): the Mayo clinic experience. Mayo Clin Proc. 2010; 85:905–
912. [PubMed: 20634497] 
4. Xie Z, Ghosh CC, Patel R, Iwaki S, Gaskins D, et al. Vascular endothelial hyperpermeability 
induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome). Blood. 
2012; 119:4321–4332. [PubMed: 22411873] 
5. Dhir V, Arya V, Malav IC, Suryanarayanan BS, Gupta R, et al. Idiopathic systemic capillary leak 
syndrome (SCLS): case report and systematic review of cases reported in the last 16 years. Intern 
Med. 2007; 46:899–904. [PubMed: 17575386] 
6. Gousseff M, Arnaud L, Lambert M, Hot A, Hamidou M, et al. The systemic capillary leak 
syndrome: a case series of 28 patients from a European registry. Ann Intern Med. 2011; 154:464–
471. [PubMed: 21464348] 
7. Abgueguen P, Chennebault JM, Pichard E. Immunoglobulins for treatment of systemic capillary 
leak syndrome. Am J Med. 2010; 123:e3–4. [PubMed: 20569743] 
8. Pecker M, Adams M, Graham W. The systemic capillary leak syndrome. Ann Intern Med. 2011; 
155:335. [PubMed: 21893630] 
Xie et al. Page 8
J Clin Cell Immunol. Author manuscript; available in PMC 2014 November 15.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t9. Tahirkheli NK, Greipp PR. Treatment of the systemic capillary leak syndrome with terbutaline and 
theophylline. A case series. Ann Intern Med. 1999; 130:905–909. [PubMed: 10375339] 
10. Doubek M, Brychtova Y, Tomiska M, Mayer J. Idiopathic systemic capillary leak syndrome 
misdiagnosed and treated as polycythemia vera. Acta Haematol. 2005; 113:150–151. [PubMed: 
15802896] 
11. Cicardi M, Berti E, Caputo V, Radice F, Gardinali M, et al. Idiopathic capillary leak syndrome: 
evidence of CD8-positive lymphocytes surrounding damaged endothelial cells. J Allergy Clin 
Immunol. 1997; 99:417–419. [PubMed: 9058699] 
12. Aranda JF, Reglero-Real N, Marcos-Ramiro B, Ruiz-Sáenz A, Fernández-Martín L, et al. 
MYADM controls endothelial barrier function through ERM-dependent regulation of ICAM-1 
expression. Mol Biol Cell. 2013; 24:483–494. [PubMed: 23264465] 
13. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol. 2001; 70:317–
325. [PubMed: 11418010] 
14. Indraccolo S, Pfeffer U, Minuzzo S, Esposito G, Roni V, et al. Identification of genes selectively 
regulated by IFNs in endothelial cells. J Immunol. 2007; 178:1122–1135. [PubMed: 17202376] 
15. Proost P, Struyf S, Loos T, Gouwy M, Schutyser E, et al. Coexpression and interaction of CXCL10 
and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are 
discriminative markers for autoimmune arthropathies. Arthritis Res Ther. 2006; 8:R107. [PubMed: 
16846531] 
16. Liu M, Guo S, Hibbert JM, Jain V, Singh N, et al. CXCL10/IP-10 in infectious diseases 
pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011; 22:121–
130. [PubMed: 21802343] 
17. Green LA, Petrusca D, Rajashekhar G, Gianaris T, Schweitzer KS, et al. Cigarette smoke-induced 
CXCR3 receptor up-regulation mediates endothelial apoptosis. Am J Respir Cell Mol Biol. 2012; 
47:807–814. [PubMed: 22936405] 
18. Assaly R, Olson D, Hammersley J, Fan PS, Liu J, et al. Initial evidence of endothelial cell 
apoptosis as a mechanism of systemic capillary leak syndrome. Chest. 2001; 120:1301–1308. 
[PubMed: 11591575] 
19. Johansson BR, Löfdahl CG. Ultrastructure of the microvessels in skeletal muscle in a case of 
systemic capillary leak syndrome. Acta Med Scand. 1979; 206:413–416. [PubMed: 525443] 
20. Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor-
induced signaling pathways in endothelial cells that mediate overexpression of the chemokine 
IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol. 2006; 176:3098–3107. 
[PubMed: 16493069] 
21. Yeruva S, Ramadori G, Raddatz D. NF-kappaB-dependent synergistic regulation of CXCL10 gene 
expression by IL-1beta and IFN-gamma in human intestinal epithelial cell lines. Int J Colorectal 
Dis. 2008; 23:305–317. [PubMed: 18046562] 
22. Lombardi A, Cantini G, Mello T, Francalanci M, Gelmini S, et al. Molecular mechanisms 
underlying the pro-inflammatory synergistic effect of tumor necrosis factor alpha and interferon 
gamma in human microvascular endothelium. Eur J Cell Biol. 2009; 88:731–742. [PubMed: 
19782427] 
23. Brownell J, Bruckner J, Wagoner J, Thomas E, Loo YM, et al. Direct, interferon-independent 
activation of the CXCL10 promoter by NF-kappaB and interferon regulatory factor 3 during 
hepatitis C virus infection. J Virol. 2014; 88:1582–1590. [PubMed: 24257594] 
24. Tang NL, Fan HP, Chang KC, Ching JK, Kong KP, et al. Genetic association between a 
chemokine gene CXCL-10 (IP-10, interferon gamma inducible protein 10) and susceptibility to 
tuberculosis. Clin Chim Acta. 2009; 406:98–102. [PubMed: 19523460] 
25. Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009; 8:379–
383. [PubMed: 19105984] 
Xie et al. Page 9
J Clin Cell Immunol. Author manuscript; available in PMC 2014 November 15.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 1. 
Clinical considerations in the prospective diagnosis of SCLS. After exclusion of primary 
cardiovascular and/or allergic causes, a diagnosis of SCLS should be entertained in patients 
with unexplained, transient hypotension and/or peripheral edema. Systemic anaphylaxis and 
hereditary and/or acquired angioedema can be excluded by measurement of serum tryptase 
during the acute episode and quantitative and functional assays for the complement 
component 1 esterase inhibitor (C1 INH). Although presumptive treatment for sepsis is 
prudent in the undiagnosed SCLS patient during the first severe episode, the hypotension 
and hemoconcentration of SCLS are typically refractory to intravenous fluid resuscitation, 
which exacerbates peripheral edema. Hypoalbuminemia due to protein extravasation is a 
hallmark of classic acute SCLS whereas low serum albumin levels and edema that does not 
resolve between episodes should prompt the diagnosis of “chronic” SCLS. MGUS is not 
universally present in SCLS and is therefore not required for the diagnosis.
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tFigure 2. 
Cytokine profiles of SCLS sera. (A–H) Serum cytokines were measured using a Bio-Plex 
Pro human multiple cytokine assay kit: VEGF (A), CXCL10 (B), CCL2 (C), IL-12 (D), 
IL-1β (E), IL-6 (F), IL-8 (G) and TNFα (H) (*P < 0.05, **P < 0.01, ****P < 0.00001 
Kruskal-Wallis).
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tFigure 3. 
Endothelial surface activation marker expression induced by SCLS sera. HUVECs were 
incubated with 10% (vol/vol) test sera for 4 hours (A–B) or 24 hours (C) at 37°C. (A) 
Surface expression of E-selectin, VCAM-1 and ICAM-1 was evaluated by flow cytometry. 
The dotted lines represent adhesion molecule expression induced by TNFα (1.25 ng/ml). (B) 
Paired comparisons of E-selectin, VCAM-1 and ICAM-1 expression induced by basal and 
episodic sera from each individual subject. (C) CXCL10 in HUVEC culture supernatants 
was measured by ELISA.
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tFigure 4. 
Abnormal IFNγ-induced CXCL10 production by PBMCs in SCLS. PBMCs were incubated 
with IFNγ and analyzed for CXCL10 production by flow cytometry. (A) Percentages of 
CXCL10+ cells among T lymphocytes (CD3+), B lymphocytes (CD19+), and monocyte 
(CD14+) populations from a representative healthy subject. (B–C) Representative flow plots 
(B) and analysis of CXCL10+ PBMCs and monocytes from SCLS subjects (n = 12) and 
healthy subjects (n = 14), presented as the fold control of the lowest value from a healthy 
donor for each individual experiment, set as ‘1’. *P = 0.02, unpaired t test.
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